Wall Street analysts expect Krystal Biotech Inc (NASDAQ:KRYS) to report ($0.27) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Krystal Biotech’s earnings. Krystal Biotech posted earnings per share of ($1.26) in the same quarter last year, which indicates a positive year-over-year growth rate of 78.6%. The business is expected to report its next quarterly earnings report on Monday, November 12th.
On average, analysts expect that Krystal Biotech will report full year earnings of ($1.04) per share for the current financial year, with EPS estimates ranging from ($1.15) to ($0.92). For the next financial year, analysts forecast that the business will report earnings of ($1.59) per share, with EPS estimates ranging from ($2.03) to ($1.26). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Krystal Biotech.
Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 6th. The company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.12.
Shares of NASDAQ:KRYS traded up $0.77 during trading on Monday, reaching $17.65. The stock had a trading volume of 78,287 shares, compared to its average volume of 52,049. Krystal Biotech has a 52 week low of $8.03 and a 52 week high of $21.17. The firm has a market cap of $174.77 million and a price-to-earnings ratio of -11.93.
Several institutional investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of Krystal Biotech in the fourth quarter worth $266,000. BlackRock Inc. grew its stake in shares of Krystal Biotech by 75.4% in the second quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after acquiring an additional 5,607 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of Krystal Biotech by 552.2% in the second quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock worth $182,000 after acquiring an additional 10,331 shares during the last quarter. Institutional investors and hedge funds own 23.07% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Further Reading: Determine Your Level of Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.